S&P 500   3,321.63 (-0.24%)
DOW   29,265.76 (-0.28%)
QQQ   223.18 (-0.09%)
AAPL   317.46 (-0.40%)
GOOGL   1,475.13 (-0.30%)
AMZN   1,870.36 (+0.30%)
CGC   24.61 (-1.12%)
NVDA   248.11 (-0.47%)
BABA   221.91 (-2.43%)
MU   58.15 (+0.85%)
GE   11.70 (-1.02%)
TSLA   542.00 (+6.17%)
AMD   51.47 (+1.06%)
T   38.36 (-0.05%)
ACB   2.06 (-3.29%)
F   9.12 (-0.44%)
NFLX   337.22 (-0.72%)
PRI   127.20 (-0.96%)
BAC   34.34 (-1.07%)
GILD   62.49 (-0.78%)
DIS   143.24 (-0.76%)
S&P 500   3,321.63 (-0.24%)
DOW   29,265.76 (-0.28%)
QQQ   223.18 (-0.09%)
AAPL   317.46 (-0.40%)
GOOGL   1,475.13 (-0.30%)
AMZN   1,870.36 (+0.30%)
CGC   24.61 (-1.12%)
NVDA   248.11 (-0.47%)
BABA   221.91 (-2.43%)
MU   58.15 (+0.85%)
GE   11.70 (-1.02%)
TSLA   542.00 (+6.17%)
AMD   51.47 (+1.06%)
T   38.36 (-0.05%)
ACB   2.06 (-3.29%)
F   9.12 (-0.44%)
NFLX   337.22 (-0.72%)
PRI   127.20 (-0.96%)
BAC   34.34 (-1.07%)
GILD   62.49 (-0.78%)
DIS   143.24 (-0.76%)
S&P 500   3,321.63 (-0.24%)
DOW   29,265.76 (-0.28%)
QQQ   223.18 (-0.09%)
AAPL   317.46 (-0.40%)
GOOGL   1,475.13 (-0.30%)
AMZN   1,870.36 (+0.30%)
CGC   24.61 (-1.12%)
NVDA   248.11 (-0.47%)
BABA   221.91 (-2.43%)
MU   58.15 (+0.85%)
GE   11.70 (-1.02%)
TSLA   542.00 (+6.17%)
AMD   51.47 (+1.06%)
T   38.36 (-0.05%)
ACB   2.06 (-3.29%)
F   9.12 (-0.44%)
NFLX   337.22 (-0.72%)
PRI   127.20 (-0.96%)
BAC   34.34 (-1.07%)
GILD   62.49 (-0.78%)
DIS   143.24 (-0.76%)
S&P 500   3,321.63 (-0.24%)
DOW   29,265.76 (-0.28%)
QQQ   223.18 (-0.09%)
AAPL   317.46 (-0.40%)
GOOGL   1,475.13 (-0.30%)
AMZN   1,870.36 (+0.30%)
CGC   24.61 (-1.12%)
NVDA   248.11 (-0.47%)
BABA   221.91 (-2.43%)
MU   58.15 (+0.85%)
GE   11.70 (-1.02%)
TSLA   542.00 (+6.17%)
AMD   51.47 (+1.06%)
T   38.36 (-0.05%)
ACB   2.06 (-3.29%)
F   9.12 (-0.44%)
NFLX   337.22 (-0.72%)
PRI   127.20 (-0.96%)
BAC   34.34 (-1.07%)
GILD   62.49 (-0.78%)
DIS   143.24 (-0.76%)
Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

NASDAQ:TWST - Twist Bioscience Stock Price, Forecast & News

$22.20
-0.54 (-2.37 %)
(As of 01/21/2020 11:06 AM ET)
Today's Range
$22.20
Now: $22.20
$23.15
50-Day Range
$20.88
MA: $23.19
$26.54
52-Week Range
$19.64
Now: $22.20
$35.95
Volume1,358 shs
Average Volume378,924 shs
Market Capitalization$738.37 million
P/E RatioN/A
Dividend YieldN/A
Beta0.71
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has a collaboration agreement with Pandion Therapeutics, Inc. to apply its antibody optimization platform for a targeting arm of a bispecific antibody. The company was founded in 2013 and is headquartered in San Francisco, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TWST
CUSIPN/A
CIKN/A
Phone800-719-0671

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.38 million
Book Value$4.63 per share

Profitability

Net Income$-107,670,000.00
Net Margins-197.98%

Miscellaneous

Employees289
Market Cap$738.37 million
Next Earnings Date2/6/2020 (Estimated)
OptionableNot Optionable

Receive TWST News and Ratings via Email

Sign-up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


What a cool story coming out of The War Room today.

One of the members made a trade on Bryan's recommendation... went to get a cup of coffee... and closed out a 33% win by the time he got back!

That's more than most people make in a year! You CANNOT miss out on these wins anymore.

Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Corp (NASDAQ:TWST) issued its quarterly earnings results on Wednesday, December, 11th. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.12. The business had revenue of $15.74 million for the quarter, compared to analysts' expectations of $14.08 million. Twist Bioscience had a negative net margin of 197.98% and a negative return on equity of 73.98%. View Twist Bioscience's Earnings History.

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Twist Bioscience.

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience issued an update on its first quarter 2020 After-Hours earnings guidance on Wednesday, December, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$15-16.5 million, compared to the consensus revenue estimate of $$15.92 million.

What price target have analysts set for TWST?

1 equities research analysts have issued 12 month target prices for Twist Bioscience's shares. Their forecasts range from $26.66 to $26.66. On average, they expect Twist Bioscience's share price to reach $26.66 in the next year. This suggests a possible upside of 15.8% from the stock's current price. View Analyst Price Targets for Twist Bioscience.

What is the consensus analysts' recommendation for Twist Bioscience?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Twist Bioscience.

Has Twist Bioscience been receiving favorable news coverage?

News stories about TWST stock have trended extremely negative on Tuesday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Twist Bioscience earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Twist Bioscience.

Are investors shorting Twist Bioscience?

Twist Bioscience saw a increase in short interest in December. As of December 31st, there was short interest totalling 4,300,000 shares, an increase of 17.5% from the December 15th total of 3,660,000 shares. Based on an average trading volume of 271,300 shares, the short-interest ratio is currently 15.8 days. Approximately 22.9% of the shares of the stock are sold short. View Twist Bioscience's Current Options Chain.

Who are some of Twist Bioscience's key competitors?

What other stocks do shareholders of Twist Bioscience own?

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the folowing people:
  • Dr. Emily Marine Leproust, Co-Founder, Pres, CEO & Director (Age 45)
  • Mr. James M. Thorburn, Chief Financial Officer (Age 64)
  • Mr. Mark Daniels Esq., Sr. VP, Chief Legal Officer, Gen. Counsel, Chief Ethics & Compliance Officer and Sec. (Age 56)
  • Mr. William Charles Banyai, COO & Director (Age 64)
  • Mr. Bill Peck, Chief Technology Officer (Age 59)

When did Twist Bioscience IPO?

(TWST) raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by many different of institutional and retail investors. Top institutional investors include Alpine Global Management LLC (0.08%). Company insiders that own Twist Bioscience stock include Bill Peck, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss and William Banyai. View Institutional Ownership Trends for Twist Bioscience.

Which institutional investors are buying Twist Bioscience stock?

TWST stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. View Insider Buying and Selling for Twist Bioscience.

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $23.02.

How big of a company is Twist Bioscience?

Twist Bioscience has a market capitalization of $765.65 million and generates $54.38 million in revenue each year. The company earns $-107,670,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Twist Bioscience employs 289 workers across the globe.View Additional Information About Twist Bioscience.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is http://www.twistbioscience.com/.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]


MarketBeat Community Rating for Twist Bioscience (NASDAQ TWST)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  98
MarketBeat's community ratings are surveys of what our community members think about Twist Bioscience and other stocks. Vote "Outperform" if you believe TWST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TWST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel